- Newsletter
- May 2026
- 2 Pages
Global
From €115EUR$131USD£99GBP
- Report
- March 2024
- 221 Pages
Global
From €2150EUR$2,450USD£1,860GBP
- Report
- October 2023
- 85 Pages
United States
From €4257EUR$4,850USD£3,682GBP
- Report
- July 2023
- 200 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- July 2023
- 218 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- July 2022
- 40 Pages
China
From €2809EUR$3,200USD£2,429GBP
- Report
- August 2019
- 42 Pages
Global
€2629EUR$2,995USD£2,274GBP
- Report
- August 2018
- 21 Pages
Global
From €8777EUR$10,000USD£7,591GBP
- Report
- April 2018
United States
From €7017EUR$7,995USD£6,069GBP
- Report
- September 2025
- 96 Pages
Global
From €3500EUR$4,272USD£3,133GBP
- Report
- September 2024
- 101 Pages
Global
From €3500EUR$4,272USD£3,133GBP
- Report
- January 2024
- 85 Pages
Global
From €3500EUR$4,272USD£3,133GBP
- Report
- October 2023
- 94 Pages
Global
From €3500EUR$4,272USD£3,133GBP
- Report
- August 2023
- 107 Pages
Global
From €3500EUR$4,272USD£3,133GBP
- Report
- January 2025
- 132 Pages
Global
From €834EUR$950USD£721GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more